Mechanistic basis of sexual dimorphism in antigen-independent IgG1 angiogenesis regulation
抗原非依赖性 IgG1 血管生成调节中性二态性的机制基础
基本信息
- 批准号:10660051
- 负责人:
- 金额:$ 68.99万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-04-01 至 2027-02-28
- 项目状态:未结题
- 来源:
- 关键词:AffinityAlzheimer&aposs DiseaseAngiogenesis InhibitorsAnimal ModelAnimalsAntibodiesAntigensBedsBiologicalBlood CellsBlood VesselsBone MarrowCardiovascular systemCellsChemotaxisChoroidal NeovascularizationComplementCoronary ArteriosclerosisDataDevelopmentDiabetic RetinopathyDiseaseEstradiolEstrogensEventExhibitsExudative age-related macular degenerationFc domainFemaleFour Core GenotypesGenesGeneticGleanGoalsGonadal HormonesGrowthGuidelinesHeart failureHindlimbHormonalHormonesHumanIgG1ImmuneInterventionIschemiaKnock-outKnowledgeMacrophageMacular degenerationMalignant NeoplasmsMediatingMediatorModelingMorbidity - disease rateMusMyocardial IschemiaNaturePathologic NeovascularizationPathway interactionsPeripheral arterial diseasePhysiologicalPlasmaPloidiesPredispositionPrevalenceProcessRegulationRegulator GenesRisk FactorsRoleSeveritiesSeverity of illnessSex BiasSex ChromosomesSex DifferencesSignal TransductionSpecimenStrokeSystemTestingTestosteroneTherapeuticTissuesUnited States National Institutes of HealthVEGFA geneY Chromosomeangiogenesisantigen bindingchromosome Y lossdimorphismgain of functiongenotypic sexhelicasehuman maleimproved outcomeinhibiting antibodyinsightknock-downloss of functionmalemortalitymosaic lossneovascularizationnovelpersonalized therapeuticpreventreceptorresponsesegregationsexsexual dimorphism
项目摘要
PROJECT ABSTRACT/SUMMARY
Diseases of excess, aberrant, or insufficient angiogenesis are responsible for a large portion of the world's
morbidity and mortality. Conditions such as peripheral artery disease, macular degeneration, coronary artery
disease, stroke, and heart failure exhibit sexual dimorphism in risk factors, prevalence, severity, or optimal
interventions. Despite widespread appreciation of these differences, the mechanisms by which sex influences
vascular conditions are incompletely understood. For example, the role of sex chromosomal complement in
angiogenic processes is ill defined. New evidence suggests that the process by which IgG1 antibodies regulate
angiogenesis in an antigen-independent manner (which we term “antibody-dependent cell-mediated
angioinhibition” or ADCAI) is strongly sexually dimorphic, with males exhibiting far greater ADCAI compared to
females. Supported by robust preliminary data, the overall hypothesis of this project is ADCAI dimorphism arises
due to expression of the Y chromosome-encoded gene DDX3Y. We will test this hypothesis in three specific
aims. 1) We will establish the precise roles of sex-biasing factors (sex chromosome complement and gonadal
secretions) in ADCAI sexual dimorphism. 2) We will determine the function of the Y chromosome-encoded
DDX3Y as a novel ADCAI regulatory gene. 3) We will quantify the sex effect on ADCAI in human cells and
specimens. Collectively, these thematically related, but independent aims will establish new foundational and
translationally relevant knowledge about the mediators and consequences of ADCAI. These studies may thereby
open new interventional avenues to modulate angiogenesis in a personalized, sex-specific manner for diverse
therapeutic applications.
项目摘要/摘要
过量,异常或血管生成不足的疾病是世界上很大一部分的疾病
发病率和死亡率。诸如外周动脉疾病,黄斑变性,冠状动脉等疾病
疾病,中风和心力衰竭在危险因素,患病率,严重程度或最佳的风险因素中暴露了性二态性
干预措施。尽管对这些差异的宽泛欣赏,但性别影响的机制
血管状况尚不完全理解。例如,性别染色体完成的作用
血管生成过程的定义不明。新证据表明,IgG1抗体调节的过程
血管生成以抗原独立的方式(我们称为抗体依赖性细胞介导的
血管抑制”或ADCAI)性二态性强烈,男性表现出更大的ADCAI
女性。在强大的初步数据的支持下,该项目的总体假设是ADCAI二态性
由于Y染色体编码的基因DDX3Y的表达。我们将以三个特定的特定方式检验该假设
目标。 1)我们将确定性别偏见因素的精确作用(性染色体完成和性腺
分泌物)在ADCAI性二态性中。 2)我们将确定Y染色体编码的功能
DDX3Y是一种新型的ADCAI调节基因。 3)我们将量化人类细胞中对ADCAI的性别影响
标本。总的来说,这些主题相关,但独立目标将建立新的基础和
关于ADCAI的介体和后果的翻译相关知识。这些研究可能因此
开放新的介入途径,以个性化的性别特定方式调节血管生成
治疗应用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Bradley David Gelfand其他文献
Bradley David Gelfand的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Bradley David Gelfand', 18)}}的其他基金
DICER1 deficiency in aberrant chorioretinal neovascularization - Administrative Supplement OKT Request
异常脉络膜视网膜新生血管形成中的 DICER1 缺陷 - 行政补充 OKT 请求
- 批准号:
10647413 - 财政年份:2021
- 资助金额:
$ 68.99万 - 项目类别:
DICER1 deficiency in aberrant chorioretinal neovascularization
DICER1 缺陷导致异常脉络膜视网膜新生血管形成
- 批准号:
10407583 - 财政年份:2021
- 资助金额:
$ 68.99万 - 项目类别:
DICER1 deficiency in aberrant chorioretinal neovascularization
DICER1 缺陷导致异常脉络膜视网膜新生血管形成
- 批准号:
10624267 - 财政年份:2021
- 资助金额:
$ 68.99万 - 项目类别:
DICER1 deficiency in aberrant chorioretinal neovascularization
DICER1 缺陷导致异常脉络膜视网膜新生血管形成
- 批准号:
10183845 - 财政年份:2021
- 资助金额:
$ 68.99万 - 项目类别:
相似海外基金
Small Molecule Degraders of Tryptophan 2,3-Dioxygenase Enzyme (TDO) as Novel Treatments for Neurodegenerative Disease
色氨酸 2,3-双加氧酶 (TDO) 的小分子降解剂作为神经退行性疾病的新疗法
- 批准号:
10752555 - 财政年份:2024
- 资助金额:
$ 68.99万 - 项目类别:
Designing novel therapeutics for Alzheimer’s disease using structural studies of tau
利用 tau 蛋白结构研究设计治疗阿尔茨海默病的新疗法
- 批准号:
10678341 - 财政年份:2023
- 资助金额:
$ 68.99万 - 项目类别:
Developing an integrated pipeline for routine generation of orthogonal GPCR-targeting nanobodies
开发用于常规生成正交 GPCR 靶向纳米抗体的集成管道
- 批准号:
10603669 - 财政年份:2023
- 资助金额:
$ 68.99万 - 项目类别:
Effect of APP copy number variants in Alzheimer's disease and and Down Syndrome on Reelin expression and function
阿尔茨海默病和唐氏综合症中 APP 拷贝数变异对 Reelin 表达和功能的影响
- 批准号:
10760161 - 财政年份:2023
- 资助金额:
$ 68.99万 - 项目类别:
Immunomodulatory ligand B7-1 targets p75 neurotrophin receptor in neurodegeneration
免疫调节配体 B7-1 在神经变性中靶向 p75 神经营养蛋白受体
- 批准号:
10660332 - 财政年份:2023
- 资助金额:
$ 68.99万 - 项目类别: